DE60307289T2 - Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit - Google Patents

Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit Download PDF

Info

Publication number
DE60307289T2
DE60307289T2 DE60307289T DE60307289T DE60307289T2 DE 60307289 T2 DE60307289 T2 DE 60307289T2 DE 60307289 T DE60307289 T DE 60307289T DE 60307289 T DE60307289 T DE 60307289T DE 60307289 T2 DE60307289 T2 DE 60307289T2
Authority
DE
Germany
Prior art keywords
compound
alkyl
hydrogen
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60307289T
Other languages
German (de)
English (en)
Other versions
DE60307289D1 (de
Inventor
A. Duane Bernardsville BURNETT
Wen-Lian Edison WU
K. Thavalakulam Edison SASIKUMAR
S. Martin Verona DOMALSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60307289D1 publication Critical patent/DE60307289D1/de
Application granted granted Critical
Publication of DE60307289T2 publication Critical patent/DE60307289T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60307289T 2002-06-27 2003-06-26 Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit Expired - Lifetime DE60307289T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
US391813P 2002-06-27
PCT/US2003/020088 WO2004002987A1 (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Publications (2)

Publication Number Publication Date
DE60307289D1 DE60307289D1 (de) 2006-09-14
DE60307289T2 true DE60307289T2 (de) 2007-10-18

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307289T Expired - Lifetime DE60307289T2 (de) 2002-06-27 2003-06-26 Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit

Country Status (14)

Country Link
US (1) US7109207B2 (enExample)
EP (1) EP1532147B1 (enExample)
JP (1) JP4522853B2 (enExample)
CN (1) CN100374440C (enExample)
AR (1) AR040344A1 (enExample)
AT (1) ATE334983T1 (enExample)
AU (1) AU2003258957A1 (enExample)
CA (1) CA2490531C (enExample)
DE (1) DE60307289T2 (enExample)
ES (1) ES2266861T3 (enExample)
MX (1) MXPA05000185A (enExample)
PE (1) PE20040749A1 (enExample)
TW (1) TW200401777A (enExample)
WO (1) WO2004002987A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
EP1601664B1 (en) * 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1867341A4 (en) * 2005-03-29 2009-07-29 Banyu Pharma Co Ltd THERAPEUTIC AGENT FOR NON-ALCOHOLIC FATBERS AND SCREENING METHODS FOR A DRUG-RELATED BIO-TREATMENT FOR THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATERS
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2072519A4 (en) * 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9090084B2 (en) 2010-05-21 2015-07-28 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
WO2001013917A1 (en) * 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE

Also Published As

Publication number Publication date
ES2266861T3 (es) 2007-03-01
PE20040749A1 (es) 2004-10-23
CA2490531C (en) 2011-03-22
DE60307289D1 (de) 2006-09-14
JP2005535641A (ja) 2005-11-24
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
CN1665812A (zh) 2005-09-07
CN100374440C (zh) 2008-03-12
EP1532147A1 (en) 2005-05-25
JP4522853B2 (ja) 2010-08-11
TW200401777A (en) 2004-02-01
HK1071567A1 (en) 2005-07-22
CA2490531A1 (en) 2004-01-08
MXPA05000185A (es) 2005-04-08
WO2004002987A1 (en) 2004-01-08
US20040024002A1 (en) 2004-02-05
EP1532147B1 (en) 2006-08-02
AU2003258957A1 (en) 2004-01-19
ATE334983T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
DE60204548T2 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
US6664273B2 (en) Piperidine based MCH antagonists for treatment of obesity and CNS disorders
US6667319B2 (en) Neuropeptide Y Y5 receptor antagonists
JP2010155848A (ja) 肥満治療用のｍｃｈアンタゴニスト
DE69919171T2 (de) Muskarin-rezeptor antagonisten
US20040034008A1 (en) New neuropeptide Y Y5 receptor antagonists
DE60213629T2 (de) Piperidinverbindungen als muscarinantagonisten
EP1532147B1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
DE602004013427T2 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
WO2005021528A1 (en) 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
JP2006520399A5 (enExample)
JP2007521286A (ja) 肥満治療用のｍｃｈアンタゴニスト
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition